HARP News and Press, Harpoon Therapeutics Inc. From 09/05/23

KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for poster presentation at the European Society for Medical Oncology (ESMO) being held October 20-24, 2023 SOUTH SAN FRAN...

2023-08-31 08:17:07 ET Dollar General DG -16% after Q2 release . OKYO Pharma ( OKYO ) -14% . Top KingWin ( TCJH ) -10% . ReTo Eco-Solutions ( RETO ) -11% . Beneficient ( BENF ) -10% . Digital Brands Group ( DBGI ) -9% . ...

2023-08-09 17:41:32 ET Harpoon Therapeutics press release ( NASDAQ: HARP ): Q2 GAAP EPS of $0.03 beats by $0.37 . Revenue of $20.22M (+143.6% Y/Y) beats by $15.08M . For further details see: Harpoon Therapeutics GAAP EPS of $0.03 beats by $0.37, revenue o...

Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society (IMS) Annual Meeting and the European Society for Medical Oncology (ESMO) in the fall Enrollment for HPN328 (DLL3) ongoing; Phase 2 dose selection expected by year end Completed plann...

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences: A corporate presentatio...

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 y...

Replicate Bioscience Appoints Rachael Lester as Chief Business Officer PR Newswire Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team SAN DIEGO , July 10,...

SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the saf...

2023-05-11 17:45:14 ET Harpoon Therapeutics press release ( NASDAQ: HARP ): Q1 GAAP EPS of -$0.31 beats by $0.08 . Revenue of $8.58M (+45.2% Y/Y) beats by $3.77M . For further details see: Harpoon Therapeutics GAAP EPS of -$0.31 beats by $0.08, revenue of...

Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023 Five preclinical posters presented at AACR 2023 in April on HPN217, HPN328 and ProTriTAC™ development ca...